Ken Fisher's CLDX Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 1.01 M shares of Celldex Therapeutics, Inc. (CLDX) worth $32.15 M, representing 0.01% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Ken Fisher has maintained a strategic position in CLDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 419,131 shares. Largest reduction occurred in Q2 2025, reducing 49,420 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Celldex Therapeutics (CLDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Celldex Therapeutics (CLDX) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +76,490 | Add 8.16% | 1.01 M | $31.72 |
| Q4 2025 | +10,001 | Add 1.08% | 937,158 | $27.16 |
| Q3 2025 | +104,949 | Add 12.76% | 927,157 | $25.87 |
| Q2 2025 | -49,420 | Reduce 5.67% | 822,208 | $20.35 |
| Q1 2025 | +419,131 | Add 92.63% | 871,628 | $18.15 |
| Q4 2024 | +78,145 | Add 20.87% | 452,497 | $25.27 |
| Q3 2024 | +253,808 | Add 210.55% | 374,352 | $33.99 |
| Q2 2024 | -3,292 | Reduce 2.66% | 120,544 | $37.01 |
| Q1 2024 | +102,024 | Add 467.74% | 123,836 | $41.97 |
| Q4 2023 | +1,274 | Add 6.20% | 21,812 | $39.66 |
| Q1 2023 | -8,479 | Reduce 29.22% | 20,538 | $35.98 |
| Q4 2022 | -4,876 | Reduce 14.39% | 29,017 | $44.56 |
| Q3 2022 | +33,893 | New Buy | 33,893 | $28.12 |
Ken Fisher's Celldex Therapeutics Investment FAQs
Ken Fisher first purchased Celldex Therapeutics, Inc. (CLDX) in Q3 2022, acquiring 33,893 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Celldex Therapeutics, Inc. (CLDX) for 15 quarters since Q3 2022.
Ken Fisher's largest addition to Celldex Therapeutics, Inc. (CLDX) was in Q1 2025, adding 871,628 shares worth $15.82 M.
According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 1,013,648 shares of Celldex Therapeutics, Inc. (CLDX), valued at approximately $32.15 M.
As of the Q1 2026 filing, Celldex Therapeutics, Inc. (CLDX) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Celldex Therapeutics, Inc. (CLDX) was 1,013,648 shares, as reported at the end of Q1 2026.